drugset / Trial / NCT00087373

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00087373

Phase 2 Terminated 28 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Vaccines may make the body build an immune response to kill tumor cells. Injecting a vaccine directly into a tumor may cause a stronger immune response and kill more tumor cells. This phase II trial is studying how well vaccine therapy works in treating patients with metastatic melanoma.

Timeline

Start
2004-06
Primary completion
2006-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject recombinant fowlpox-TRICOM vaccine Vaccine Other

Indications